TG
VRTX icon

TLP Group’s Vertex Pharmaceuticals VRTX Stock Holding History

TLP Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-5
Closed -$1K – 559
2018
Q2 		$1K Sell
5
-1,245
-100% -$193K ﹤0.01% 354
2018
Q1 		$204K Buy
+1,250
New +$204K 0.14% 240
2017
Q4 		– Sell
-1,816
Closed -$276K – 736
2017
Q3 		$276K Buy
+1,816
New +$273K 0.17% 147

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

TLP Group's VRTX Position: Q3 2018 in Review

TLP Group sold out of Vertex Pharmaceuticals (VRTX) in Q3 2018, closing a stake of 5 shares — an estimated $1K sold.

TLP Group first reported a position in VRTX in Q3 2017 and held it in 3 quarters. The position peaked at $276K in Q3 2017. 696 funds tracked by Wall St. Rank hold VRTX as of Q3 2018.

  • TLP Group reported no remaining Vertex Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • TLP Group sold 5 Vertex Pharmaceuticals shares in Q3 2018, an estimated $1K.
  • TLP Group first reported a position in Vertex Pharmaceuticals in Q3 2017 and held it in 3 quarters.
  • TLP Group's Vertex Pharmaceuticals position peaked at $276K in Q3 2017.
  • 696 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2018.

Based on TLP Group's 13F filing for Q3 2018, filed 14 Nov 2018.